NL-1

• Description :

  NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Autophagy; Mitochondrial Metabolism

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/nl-1.html

• Purity :

  99.45

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  O=C(N1)SC(CC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C1=O

• Molecular Formula :

  C18H25NO3S

• Molecular Weight :

  335.46

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370 (1) :25-34.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [188532-26-5]